Last reviewed · How we verify
Pegasys(Roche)
Pegasys is a pegylated interferon alfa-2a that activates innate immune responses to suppress viral replication and inhibit cell proliferation.
Pegasys is a pegylated interferon alfa-2a that activates innate immune responses to suppress viral replication and inhibit cell proliferation. Used for Chronic hepatitis C virus infection, Chronic hepatitis B virus infection, Melanoma (adjuvant therapy).
At a glance
| Generic name | Pegasys(Roche) |
|---|---|
| Also known as | peginterferon alfa-2a |
| Sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Pegylated interferon alfa-2a |
| Target | Interferon alfa receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Virology / Oncology |
| Phase | Phase 3 |
Mechanism of action
Pegasys works by binding to interferon alfa receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral and antiproliferative genes. This leads to enhanced natural killer cell and cytotoxic T-lymphocyte activity, reduced viral protein synthesis, and inhibition of cell division. The pegylation extends the drug's half-life, allowing for once-weekly dosing instead of multiple weekly injections.
Approved indications
- Chronic hepatitis C virus infection
- Chronic hepatitis B virus infection
- Melanoma (adjuvant therapy)
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression / mood changes
- Alopecia
- Anemia
Key clinical trials
- Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment (PHASE3)
- An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
- A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
- Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) (PHASE3)
- Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C (PHASE4)
- The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C
- Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV (PHASE2)
- HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegasys(Roche) CI brief — competitive landscape report
- Pegasys(Roche) updates RSS · CI watch RSS
- Third Affiliated Hospital, Sun Yat-Sen University portfolio CI